key: cord-0743515-tlt1f1wx
authors: Sakthivel, P; Ish, P
title: COVID-19-associated mucormycosis—elucidating the etiology of this emerging entity
date: 2021-07-15
journal: QJM
DOI: 10.1093/qjmed/hcab195
sha: f5eead4ad52e5a8ef7a7223b1b79e61e148e57bb
doc_id: 743515
cord_uid: tlt1f1wx

nan

With great interest, we read the article by Sarda et al. 1 and would like to congratulate the authors for discussing the emerging epidemic of COVID-19-associated Mucormycosis (CAM) and the risk factors including excessive use of steroids, hyperglycemia, home management and hyperferritinemia, prolonged face masks and industrial oxygen. The evidence for the same, however, is lacking.

A recent study by MucoCovi Network in India, 2 the country severely affected by the deadly duos has attempted to decipher the risk factors for occurrence, severity and outcome of CAM. The authors provided clear facts that the increased incidence (2.1-fold rise) of mucormycosis in India during the first wave is only because of COVID-19, by comparing the incidence of the disease with the previous year. The authors also observed newly detected diabetes mellitus was more frequent during the evaluation of mucormycosis among CAM (39/187 [20.9%]) than non-CAM (10/ 100 [10%]; P ¼ 0.02) patients indicating diabetes mellitus (treatment or COVID-19 induced) as a strong risk factor for the development of CAM. 48/61 (78.7%) patients who had CAM received glucocorticoid treatment for COVID-19 management and had no other comorbidities indicating possible steroid association for CAM. However, the article does not dwell on the reasons for this epidemic of Mucor among the COVID-19 pandemic. The authors apart from the known risk factors (diabetes, steroid use and hypoxemia) have not probed into the mechanism of the association of COVID-19, its treatment-related factors with mucormycosis.

Over 14 000 cases of CAM have been reported from India till 28th may 2021. 3 This huge burden has forced the administration, public health experts, doctors and hospitals to implement preventive, rapid diagnostic and treatment guidelines for containment and favorable outcome. However, prevention is probably the best weapon against CAM that requires control of all risk factors. Data pertaining to other factors like newer variants (Delta variant) of virus, unhygienic ventilation systems, use of industrial oxygen, cytokine storm need to be collected to understand the disease pathogenesis better. 4, 5 Epidemiological and large-scale basis ambispectively to understand the exact etiopathogenesis of CAM are urgently needed. This understanding can help in the prevention of another exponential spurt of CAM in developing nations like India and also for the benefit of the mankind.

Conflict of interest: None declared.

COVID-19 associated mucormycosis: an epidemic within a pandemic

Multicenter epidemiologic study of coronavirus disease-associated mucormycosis

Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?

COVID-19-associated mucormycosis: an updated systematic review of literature

Mucormycosis: time to address this deadly fungal infection